Delivery Order SPE2DB24D1104-SPE2DB25FYDT4
- Not listed
- The Defense Logistics Agency awarded a $3,198.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (quantity: 30 units), with an ultimate completion date of June 20, 2025. This non-set-aside competitive award was issued on June 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a $39,485.33 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 23, 2025, with ultimate completion by July 24, 2025. This firm fixed-price, non-set-aside contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XELJANZ XR 11 MG tablets in 30-count units. This is a firm fixed price, non-set-aside contract with performance completion scheduled for July 29, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location in the same city. The contract represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $48,891.75 to AmerisourceBergen Drug Corp for supply of XELJANZ XR 11 mg tablets (30-count units). The contract is a firm fixed price delivery order with an ultimate completion date of June 17, 2025, and represents a non-competitive award. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract represents a non-set-aside award made through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,373.92 under a firm fixed-price contract type. This is a non-set-aside award issued on September 23, 2025, with an ultimate completion date of September 24, 2025. The contractor will perform from its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units, with a contract ceiling value of $17,613.10. This competitively awarded, non-set-aside delivery order reflects a firm fixed-price arrangement with a completion date of September 3, 2025. The order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion master...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $17,873.07 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on August 8, 2025, for XELJANZ XR 11 mg tablets (30-count packages). The award, which carries an ultimate completion date of August 11, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $24,257.92 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price arrangement. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYDT4Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $11,557.68 delivery order for XELJANZ XR 11 mg tablets (30-count units) under a competitive, non-set-aside procurement. The award was issued on July 25, 2025, with an ultimate completion date of July 28, 2025, and represents a firm fixed-price transaction. This delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. The contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements through open competition, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for XELJANZ XR—a rheumatoid arthritis treatment—exemplifies the company's role in supplying essential medications to Defense Health Agency and other government healthcare systems through its comprehensive IDC vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 7/25/25 |